Squarepoint Ops LLC Cuts Stock Holdings in ProQR Therapeutics (NASDAQ:PRQR)

Squarepoint Ops LLC trimmed its stake in shares of ProQR Therapeutics (NASDAQ:PRQR) by 44.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 84,733 shares of the biopharmaceutical company’s stock after selling 67,769 shares during the period. Squarepoint Ops LLC’s holdings in ProQR Therapeutics were worth $141,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Privium Fund Management B.V. lifted its position in ProQR Therapeutics by 4.4% during the second quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock valued at $9,208,000 after purchasing an additional 236,279 shares during the last quarter. Ikarian Capital LLC lifted its position in ProQR Therapeutics by 2.3% during the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock valued at $1,098,000 after purchasing an additional 10,958 shares during the last quarter. BNP Paribas Financial Markets lifted its position in ProQR Therapeutics by 120.1% during the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 19,100 shares during the last quarter. RFG Advisory LLC bought a new position in ProQR Therapeutics during the first quarter valued at $73,000. Finally, Acadian Asset Management LLC bought a new position in ProQR Therapeutics during the first quarter valued at $56,000. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Trading Down 1.6 %

NASDAQ:PRQR opened at $1.85 on Monday. The company has a market cap of $150.51 million, a PE ratio of -5.00 and a beta of 0.39. ProQR Therapeutics has a twelve month low of $1.11 and a twelve month high of $3.29. The company’s 50 day moving average is $1.92 and its two-hundred day moving average is $1.91.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.09. ProQR Therapeutics had a negative net margin of 140.17% and a negative return on equity of 55.42%. The business had revenue of $6.79 million during the quarter, compared to analysts’ expectations of $3.32 million. As a group, analysts expect that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of ProQR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 29th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $3.38.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).